Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEP-ruxolitinib for Refractory/Relapsed HLH
NCT03533790Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT03533790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533790.